Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,280 across all filing types
Latest filing 2024-08-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
关于调整董事会审计委员会委员的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the adjustment of members of the Board Audit Committee. It details changes in the composition of the audit committee members, including names and roles before and after the adjustment. There is no financial data, no mention of a report being published or attached, and no reference to voting results or other report types. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management committees.
2024-08-28 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2024 半年度报告摘要" which translates to "2024 Semi-Annual Report Summary." It contains detailed financial data such as revenue, net profit, cash flow, earnings per share, and net asset values for the half-year period. It also includes information about shareholders, stock holdings, and significant company events during the reporting period. The length of the document (5761 characters) and the presence of substantive financial data and analysis confirm it is a financial report rather than a brief announcement or certification. The document is a comprehensive interim report covering a period shorter than a full fiscal year, consistent with the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-28 Chinese
2024年半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 90% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the half-year period of 2024. It includes specific financial figures, accounting subjects, and relationships with related parties. The presence of detailed financial data for a half-year period indicates it is a substantive financial report rather than a brief announcement or certification. The document length is 3021 characters, which is relatively short but contains actual financial data and analysis for a half-year period. This matches the definition of an Interim / Quarterly Report (IR), which covers comprehensive financial data for a period shorter than a full fiscal year. There is no indication that this is an announcement or a certification, so it should not be classified as RPA or RNS. Therefore, the most appropriate classification is IR (Interim / Quarterly Report). H1 2024
2024-08-28 Chinese
公司章程修订对照表
Governance Information Classification · 95% confidence The document is a detailed comparison table of amendments to the company's Articles of Association (公司章程修订对照表) approved by the board and pending shareholder meeting approval. It discusses changes to governance rules, shareholder rights, board and meeting procedures, profit distribution policies, and other corporate governance matters. There is no financial data, earnings information, or audit content. The document is not a report of financial results or an announcement of voting results but a governance-related document detailing internal rules and corporate governance practices. Therefore, it fits the category of Governance Information (CGR). The document length is over 10,000 characters, indicating it is the actual document, not just an announcement of publication.
2024-08-28 Chinese
关于召开2024年第一次临时股东会的通知
AGM Information Classification · 95% confidence The document is a notice for convening the 2024 first extraordinary general meeting of shareholders of Guangzhou Xiangxue Pharmaceutical Co., Ltd. It details the meeting date, voting procedures, registration requirements, and agenda items for shareholder approval. It does not contain financial statements, audit results, or management discussion and analysis. It is a formal announcement about the meeting logistics and agenda, not the meeting materials or results themselves. The document length is about 4300 characters, which is relatively short and consistent with a meeting notice. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or about the Annual or Extraordinary General Meeting, including notices of meetings.
2024-08-28 Chinese
股东会议事规则
Governance Information Classification · 95% confidence The document is titled as "股东会议事规则" which translates to "Rules of Procedure for Shareholders' Meetings" for 广州市香雪制药股份有限公司. It extensively details the procedures, powers, and regulations governing the conduct of shareholders' meetings, including the rights and responsibilities of shareholders, board members, and other participants. It does not contain financial statements, earnings data, or audit results. It is not a report of financial performance or an announcement of voting results but rather a governance document outlining internal rules and procedures related to shareholder meetings. Therefore, it fits best under Governance Information (CGR). The document length is substantial and contains detailed governance rules, supporting a high confidence classification.
2024-08-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.